2 results
Approved WMORecruiting
Primary: To assess the proportion of patients with intervention failure at 12 months after dose reduction, defined as patients who have restarted their initial dose due to (expected) loss of major molecular response.
Approved WMORecruiting
Main objective- to investigate the effect of alfacalcidol on the treatment of secondary hyperparathyroidism in patients after RYGB Secondary objectives: - to investigate bone turnover and changes in BMD in relation to secondary hyperparathyroidism…